Skip to main content
Midas Edge

Mirum Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity (Deficit)
Shares · Amount
Balance as of December 31, 202551,896,391$5$981,878$(667,544)$351$314,690
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,6003,385,149—259,948——259,948
Issuance of common stock in connection with asset acquisition4,404,1901415,270——415,271
Stock-based compensation in connection with asset acquisition112,872—10,643——10,643
Issuance of common stock in connection with equity award plans1,127,563—10,131——10,131
Stock-based compensation——22,345——22,345
Net loss———(790,155)—(790,155)
Other comprehensive loss————(379)(379)
Balance as of March 31, 202660,926,165$6$1,700,215$(1,457,699)$(28)$242,494
Issuance of common stock in connection with equity award plans560,812—11,304——11,304
Issuance of common stock in connection with employee stock purchase plan47,162—2,859——2,859
Conversion of convertible notes, net31—1——1
Exchange and repurchase of convertible notes maturing in 2029——(558,901)——(558,901)
Shares issued in connection with the exchange and repurchase of convertible notes maturing in 20293,220,529—329,089——329,089
Stock-based compensation——30,605——30,605
Net loss———(67,227)—(67,227)
Other comprehensive loss————(646)(646)
Balance as of June 30, 202664,754,699$6$1,515,172$(1,524,926)$(674)$(10,422)
Issuance of common stock in connection with equity award plans454,68117,164——7,165
Conversion of convertible notes, net94—3——3
Repurchase of convertible notes maturing in 2029——(41,980)——(41,980)
Stock-based compensation——33,196——33,196
Net loss———(40,766)—(40,766)
Other comprehensive loss————(1,382)(1,382)
Balance as of September 30, 202665,209,474$7$1,513,555$(1,565,692)$(2,056)$(54,186)

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202448,338,096$5$870,189$(644,181)$(373)$225,640
Issuance of common stock in connection with equity award plans1,112,939—6,359——6,359
Conversion of convertible notes, net188—6——6
Stock-based compensation——15,813——15,813
Net loss———(14,677)—(14,677)
Other comprehensive income————115115
Balance as of March 31, 202549,451,223$5$892,367$(658,858)$(258)$233,256
Issuance of common stock in connection with equity award plans547,323—6,575——6,575
Issuance of common stock in connection with employee stock purchase plan59,752—2,113——2,113
Conversion of convertible notes, net94—3——3
Stock-based compensation——18,462——18,462
Net loss———(5,861)—(5,861)
Other comprehensive income————610610
Balance as of June 30, 202550,058,392$5$919,520$(664,719)$352$255,158
Issuance of common stock in connection with equity award plans1,255,533—16,096——16,096
Conversion of convertible notes, net251—8——8
Stock-based compensation——18,194——18,194
Net income———2,905—2,905
Other comprehensive loss————(315)(315)
Balance as of September 30, 202551,314,176$5$953,818$(661,814)$37$292,046
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.